Description
Is Fruquin 5 mg right for your situation?
Review these criteria with your oncologist before enquiring- ✓Metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy
- ✓Previously treated with anti-VEGF therapy, and anti-EGFR therapy if RAS wild-type
- ✓Considering third- or fourth-line treatment after prior options have stopped working
- ✓Need a WHO-GMP generic alternative to Fruzaqla® (Takeda/HUTCHMED)
- ✗History of severe haemorrhage or significant cardiac disease without close monitoring
- ✗Uncontrolled hypertension
- ✗Surgery planned within 2 weeks (wound healing risk)
- ✗Pregnant, planning pregnancy, or breastfeeding
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Fruquin 5 mg?
Fruquin 5 mg is a generic formulation of Fruquintinib — a highly selective oral inhibitor of VEGFR-1, -2, and -3 — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each capsule contains 5 mg of fruquintinib, the same active molecule found in Fruzaqla® (Takeda/HUTCHMED), and is dispensed under the Named Patient Program.
Fruquintinib works by blocking tumour angiogenesis — cutting off the new blood vessel formation that colorectal tumours rely on to grow and spread — rather than through direct cytotoxic chemotherapy.
| Generic name | Fruquintinib |
| Reference brand | Fruzaqla® (Takeda / HUTCHMED) |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | Selective VEGFR Inhibitor |
| Dosage form | Capsule — 5 mg |
| Pack size | 21 capsules (1-month supply) |
| Route | Oral · once daily, 21 days on / 7 days off |
| Prescription | Required — oncologist only |
How Fruquintinib Works
Tumours require continuous formation of new blood vessels (angiogenesis) to receive the oxygen and nutrients needed for growth and metastasis, a process driven largely by VEGFR signalling.
What to Expect: First 30 Days
- Before starting: Baseline blood pressure and liver function are checked. Wound healing should be complete if you have had recent surgery.
- Days 1–21 (on-treatment): Hypertension is common and weekly monitoring is recommended during this window. Hand-foot syndrome (palmar-plantar erythrodysesthesia) may develop — redness, swelling, or pain on palms and soles.
- Days 22–28 (off-treatment): The 7-day break allows recovery from cumulative side effects before the next cycle begins. Voice changes (dysphonia) and protein in the urine may also be monitored during routine visits.
Side Effects
Common · Usually Manageable (≥20%)
- Hypertension
- Hand-foot syndrome (PPE)
- Dysphonia (voice changes)
- Proteinuria
- Fatigue
- Diarrhoea
Serious · Report Immediately
- Severe hemorrhage
- Cardiac events
- Impaired wound healing
- Severe hypertension
- Unusual bleeding, blood in stool/urine, or coughing/vomiting blood
- Chest pain, irregular heartbeat, or severe shortness of breath
- Severe headache or very high home blood pressure reading
How to Take Fruquin 5 mg
Standard dose: 5 mg once daily for 21 consecutive days, followed by 7 days off — a complete 28-day cycle. Continue until disease progression or unacceptable toxicity.
- 121 days on, 7 days off — track this cycle carefully; missing the pattern reduces effectiveness or increases toxicity risk.
- 2Swallow capsule whole with water. Do not crush or chew. Can be taken with or without food.
- 3Discontinue at least 2 weeks before planned surgery, including dental procedures, due to wound-healing risk. Confirm exact timing with your surgical team.
- 4Storage: below 30°C, dry place, out of reach of children.
Frequently Asked Questions
Is Fruquin the same as Fruzaqla?
Why is the 21/7 cycle important?
What line of treatment is Fruquin typically used for?
How do I order Fruquin through Meds For Cancer?
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.
- Dasari A, et al. Fruquintinib versus placebo in refractory metastatic colorectal cancer (FRESCO-2). Lancet 2023;402:41–53.
- FDA Prescribing Information: Fruzaqla (fruquintinib). Takeda, 2023.
Reviews
There are no reviews yet.